PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1999 September; 92(9): 456–461.
PMCID: PMC1297356

Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Savage CO, Harper L, Adu D. Primary systemic vasculitis. Lancet. 1997 Feb 22;349(9051):553–558. [PubMed]
  • Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187–192. [PubMed]
  • Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997 Nov 20;337(21):1512–1523. [PubMed]
  • Ewert BH, Jennette JC, Falk RJ. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis. 1991 Aug;18(2):188–195. [PubMed]
  • Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol. 1991 Dec;50(6):539–546. [PubMed]
  • Reumaux D, Vossebeld PJ, Roos D, Verhoeven AJ. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood. 1995 Oct 15;86(8):3189–3195. [PubMed]
  • Gilligan HM, Bredy B, Brady HR, Hébert MJ, Slayter HS, Xu Y, Rauch J, Shia MA, Koh JS, Levine JS. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med. 1996 Dec 1;184(6):2231–2241. [PMC free article] [PubMed]
  • Savage CO, Gaskin G, Pusey CD, Pearson JD. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol. 1993 May-Jun;1(3):190–195. [PubMed]
  • Sibelius U, Hattar K, Schenkel A, Noll T, Csernok E, Gross WL, Mayet WJ, Piper HM, Seeger W, Grimminger F. Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J Exp Med. 1998 Feb 16;187(4):497–503. [PMC free article] [PubMed]
  • Dolman KM, van de Wiel BA, Kam CM, Kerrigan JE, Hack CE, von dem Borne AE, Powers JC, Goldschmeding R. Proteinase 3: substrate specificity and possible pathogenetic effect of Wegener's granulomatosis autoantibodies (c-ANCA) by dysregulation of the enzyme. Adv Exp Med Biol. 1993;336:55–60. [PubMed]
  • Esnault VL, Testa A, Audrain M, Rogé C, Hamidou M, Barrier JH, Sesboü R, Martin JP, Lesavre P. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int. 1993 Jun;43(6):1329–1332. [PubMed]
  • Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant. 1996 Mar;11(3):438–443. [PubMed]
  • Gaskin G, Savage CO, Ryan JJ, Jones S, Rees AJ, Lockwood CM, Pusey CD. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant. 1991;6(10):689–694. [PubMed]
  • Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM. 1995 Feb;88(2):127–133. [PubMed]
  • De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis. 1995 Mar;25(3):380–389. [PubMed]
  • Tervaert JW, Huitema MG, Hené RJ, Sluiter WJ, The TH, van der Hem GK, Kallenberg CG. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990 Sep 22;336(8717):709–711. [PubMed]
  • Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, Donker AJ, von dem Borne AE, Goldschmeding R. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 1993 Sep 11;342(8872):651–652. [PubMed]
  • Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr. 1994 Jun;124(6):986–988. [PubMed]
  • D'Cruz D, Chesser AM, Lightowler C, Comer M, Hurst MJ, Baker LR, Raine AE. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol. 1995 Nov;34(11):1090–1091. [PubMed]
  • Heeringa P, Brouwer E, Tervaert JW, Weening JJ, Kallenberg CG. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int. 1998 Feb;53(2):253–263. [PubMed]
  • Griffith ME, Pusey CD. HLA genes in ANCA-associated vasculitides. Exp Clin Immunogenet. 1997;14(3):196–205. [PubMed]
  • Giscombe R, Grunewald J, Nityanand S, Lefvert AK. T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol. 1995 Aug;101(2):213–219. [PubMed]
  • Simpson IJ, Skinner MA, Geursen A, Peake JS, Abbott WG, Fraser JD, Lockwood CM, Tan PL. Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis. Clin Exp Immunol. 1995 Aug;101(2):220–226. [PubMed]
  • Stegeman CA, Tervaert JW, Huitema MG, Kallenberg CG. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol. 1993 Mar;91(3):415–420. [PubMed]
  • Lúdvíksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, Fauci AS, Strober W. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol. 1998 Apr 1;160(7):3602–3609. [PubMed]
  • Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum. 1992 Sep;35(9):1088–1096. [PubMed]
  • Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK. Relapses in Wegener's granulomatosis: the role of infection. Br Med J. 1980 Sep 27;281(6244):836–838. [PMC free article] [PubMed]
  • Sitara D, Hoffbrand BI. Chronic bronchial suppuration and antineutrophil cytoplasmic antibody (ANCA) positive systemic vasculitis. Postgrad Med J. 1990 Aug;66(778):669–671. [PMC free article] [PubMed]
  • Stegeman CA, Tervaert JW, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis and follow-up in systemic vasculitis. Ann Med Interne (Paris) 1994;145(8):523–532. [PubMed]
  • Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4;335(1):16–20. [PubMed]
  • Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76–85. [PubMed]
  • Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997 Aug;72(8):737–747. [PubMed]
  • Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991 Oct;40(4):757–763. [PubMed]
  • Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991 May 11;337(8750):1137–1139. [PubMed]
  • Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM. 1996 Dec;89(12):903–912. [PubMed]
  • Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, Savage CO, Bacon PA. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997 Jun;90(6):391–399. [PubMed]
  • Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 1998 Jul;9(7):1258–1263. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press